A stool resuspension solution comprising a hemoglobin stabilization reagent is provided. In some embodiments, the hemoglobin stabilization reagent may be an osmolyte, a polyvalent cation, a sugar or polysaccharide and, optionally, a polyvalent cation, a protoporphyrin, or an HRP stabilization component and, optionally, a polyvalent cation. A method of stabilizing hemoglobin in a stool sample in the solution is also provided, as well as a sample collection device containing the solution.

The present application provides a removable reagent pack for use in an in-vitro diagnostic device. The removable reagent pack internally includes a calibration solution bag, a calibration solution output pipeline, a valve part, a pump, and an air pipeline, wherein the calibration solution output pipeline is connected to a first end of the valve part, the air pipeline is connected to a second end of the valve part, and a third end of the valve part is connected to an external interface of the reagent pack by means of the pump. The removable reagent pack is suitable for independent transportation and storage, and the reagent pack can be reused many times because the readable device is provided with a device allowing for reading factory information and use status.

The present disclosure provided a blood cell analyzer, a control device and a blood analysis method thereof. In the method, a first reagent is mixed with a sample to obtain a first testing sample, and then a second reagent is mixed with the first testing sample for a further reaction to get a second testing sample for basophil classification and/or HGB measurement. A blood sample may be tested in one reaction cell through time-division multiplexing technology to obtain four groups leukocytes classification result and HGB result by single detection channel. Thus, the structure of the analyzer may be greatly simplified on the premise of guaranteeing the performance of the analyzer, the size and cost of the analyzer may reduce and a performance-price ratio of the analyzer may increase.

An object of the present invention is to provide a blood analysis method and a blood test kit, which are capable of performing measurement of a plurality of target components to be analyzed with high accuracies in a case where hemolysis occurs in a case of measuring an amount of target components to be analyzed in a small volume of a blood sample. According to the present invention, provided is a blood analysis method for measuring a concentration of a target component to be analyzed, the blood analysis method including: a step of diluting a collected blood sample with a diluent solution, a step of determining a dilution factor by using a normal value of a normal component which is homeostatically present in blood, a step of analyzing the concentration of the target component to be analyzed in the blood sample, measuring an amount of hemolysis in the blood sample, correcting the dilution factor according to the measured amount of hemolysis, and analyzing the concentration of the target component to be analyzed using the corrected dilution factor.

The invention relates to a method for detecting an analyte present in a liquid specimen, including: injecting the liquid specimen into a detection chamber, the detection chamber having a non-zero volume enclosing polymeric beads covered with a reagent suitable for the analyte to be detected; capturing at least one image of at least one region of the detection chamber using a sensor; processing the image acquired by the sensor, which includes determining a texture level of the acquired image; and determining a concentration of the analyte depending on the texture level determined for the image.

A diagnostic system detects and/or measures hemoglobin and/or hemoglobin variants in blood of subject to determine hemoglobin levels, hemoglobin variants, and/or anemia in the subject.

A method for determining a non-anticoagulant interferent in a blood-derived sample of a subject, the method comprising a) determining a value of a coagulation time-related parameter in the sample; b) comparing the value of the coagulation time-related parameter determined in a) to a value of the coagulation time-related parameter determined in at least one reference sample; and c) based on the result of comparison step b), determining the non-anticoagulant interferent in a blood-derived sample of a subject. A method for identifying a blood-derived sample having insufficient quality is further disclosed, the method comprising determining non-anticoagulant interferent(s) according to the aforesaid method.

A sample analyzer prepares a measurement sample from a blood sample or a body fluid sample which differs from the blood sample; measures the prepared measurement sample; obtains characteristic information representing characteristics of the components in the measurement sample; sets either a blood measurement mode for measuring the blood sample, or a body fluid measurement mode for measuring the body fluid sample as an operating mode; and measures the measurement sample prepared from the blood sample by executing operations in the blood measurement mode when the blood measurement mode has been set, and measuring the measurement sample prepared from the body fluid sample by executing operations in the body fluid measurement mode that differs from the operations in the blood measurement mode when the body fluid measurement mode has been set, is disclosed. A computer program product is also disclosed.

The present invention provides for systems and methods for inhaled CO therapy to prevent, attenuate, or delay processes that accelerate the loss of organ or tissue function, thereby increasing the lifespan of transplanted organs or tissues, or slowing the decline of native organs or tissues, or delaying the need for replacement of diseased native organs with organ transplants. Such biological processes that are prevented, attenuated, or delayed include chronic persistent inflammation, fibrosis, scarring, as well as immunologic or autoimmune attack.

A method of mass spectrometry determines if a mutated variant of a target protein is present in a sample. The method includes subjecting the sample to fragmentation so as to cause the target protein to fragment to form second generation fragment ions, and then mass analysing these fragment ions to obtain spectral data. The method determines if a mutated variant is present in the sample by determining that an ion in the spectral data has a mass to charge ratio that differs from the mass to charge ratio of an ion that would be observed if the target protein was a normal unmutated version of the target protein, and by an amount that corresponds to a mass difference that would be caused by the target protein being a mutated variant of the target protein.